| Name | Title | Contact Details |
|---|
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Synergy is a gastrointestinal-focused biopharmaceutical company committed to science-based innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.
Modigene Inc. is a Vienna, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cobalt Pharmaceuticals Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.